217 related articles for article (PubMed ID: 11771154)
1. Parkinson's disease. A half century of progress.
Jankovic J
Neurology; 2001 Nov; 57(10 Suppl 3):S1-3. PubMed ID: 11771154
[No Abstract] [Full Text] [Related]
2. [L-dopa: a fascinating history].
García de Yébenes J; García Ruiz P
Neurologia; 1998; 13 Suppl 1():36-40. PubMed ID: 9859684
[No Abstract] [Full Text] [Related]
3. [Short history of L-Dopa].
García Ruiz PJ; Meseguer E
Neurologia; 2002 Apr; 17(4):214-7. PubMed ID: 11940409
[TBL] [Abstract][Full Text] [Related]
4. Levodopa: 50 years of a revolutionary drug for Parkinson disease.
Fahn S; Poewe W
Mov Disord; 2015 Jan; 30(1):1-3. PubMed ID: 25488146
[No Abstract] [Full Text] [Related]
5. How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago.
Hornykiewicz O
Wien Klin Wochenschr; 2001 Nov; 113(22):855-62. PubMed ID: 11762121
[No Abstract] [Full Text] [Related]
6. The history of dopamine and levodopa in the treatment of Parkinson's disease.
Fahn S
Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
[TBL] [Abstract][Full Text] [Related]
7. Levodopa: past, present, and future.
Hauser RA
Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
[TBL] [Abstract][Full Text] [Related]
8. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.
Birkmayer W; Hornykiewicz O
Wien Klin Wochenschr; 2001 Nov; 113(22):851-4. PubMed ID: 11763859
[No Abstract] [Full Text] [Related]
9. [Madopar: more than 20 years].
Leiva C
Rev Neurol; 1997 Dec; 25(148):1957-63. PubMed ID: 9528041
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA.
Hornykiewicz O
J Parkinsons Dis; 2017; 7(s1):S3-S10. PubMed ID: 28282813
[No Abstract] [Full Text] [Related]
11. Background to the levodopa treatment of Parkinson's disease.
Sourkes TL
Prim Care; 1977 Sep; 4(3):529-32. PubMed ID: 400852
[No Abstract] [Full Text] [Related]
12. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
Hornykiewicz O
Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
[TBL] [Abstract][Full Text] [Related]
13. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
14. Levodopa. Is toxicity a myth? 1998.
Agid Y
Neurology; 2001 Nov; 57(10 Suppl 3):S46-51. PubMed ID: 11775601
[No Abstract] [Full Text] [Related]
15. The history of drugs for the treatment of Parkinson's disease.
Kapp W
J Neural Transm Suppl; 1992; 38():1-6. PubMed ID: 1491242
[TBL] [Abstract][Full Text] [Related]
16. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. 2000.
Fraix V; Pollak P; Van Blercom N; Xie J; Krack P; Koudsie A; Benabid AL
Neurology; 2001 Nov; 57(10 Suppl 3):S60-2. PubMed ID: 11775603
[No Abstract] [Full Text] [Related]
17. Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s.
Santos-Lobato BL; Tumas V
Arq Neuropsiquiatr; 2016 Aug; 74(8):687-9. PubMed ID: 27556381
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
Djamshidian A; Poewe W
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
[TBL] [Abstract][Full Text] [Related]
19. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
20. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
